syngo.CT LVO Detection

syngo.CT LVO Detection is a radiological post-processing software designed for computer-aided triage to identify findings suspicious of large vessel occlusion (LVO) in CT angiography (CTA) head images. Its substantial equivalence was determined through comprehensive software verification, validation, and performance testing, demonstrating high sensitivity and specificity on retrospective datasets.

Siemens Medical Solutions USA, Inc. received a determination on April 10, 2025, regarding their device, syngo.CT LVO Detection. This software functions as a radiological post-processing application for the analysis of CT angiography (CTA) head images. Its purpose is to support computer-aided triage by identifying findings suspicious of large vessel occlusion (LVO) in the ICA, M1, and M2 segments of the brain. Intended for patients aged 22 years and older (excluding those with certain contraindications like old infarcts, brain tumors, or metal artifacts), the device provides output for informational purposes only, does not serve as a diagnostic tool, and does not alter the original medical images. The review concluded that syngo.CT LVO Detection is substantially equivalent to legally marketed predicate devices for its specified indications for use. This conclusion was based on comprehensive software verification and validation, as well as performance data from standalone testing. The device was evaluated on 602 retrospective CT datasets, achieving an observed sensitivity of 90.6% and a specificity of 88.8%, both exceeding predefined acceptance thresholds. The manufacturer confirmed compliance with various recognized consensus standards, supporting the device's safety and effectiveness.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does syngo.CT LVO Detection differentiate between LVOs and other vascular abnormalities or artifacts in CTA images?; What is the clinical impact of using this device for computer-aided triage on patient outcomes, such as time to treatment or neurological recovery?; Given its "informational purposes only" status, what are the specific clinical workflows where this device is most effectively integrated without causing diagnostic confusion?; Were there specific types of LVOs (e.g., location, thrombus characteristics) or patient demographics that influenced the device's sensitivity and specificity performance?; What post-market surveillance or real-world evidence studies are planned to further evaluate the long-term performance and safety of syngo.CT LVO Detection?